Skip to main content

Advertisement

SpringerLink
Log in

Effects of Amlodipine, Captopril, and Bezafibrate on Oxidative Milieu in Rats with Fatty Liver

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Oxidative stress may initiate significant hepatocyte injury in subjects with fatty liver. We characterized changes in hepatic oxidative anti-oxidative parameters in rats given a fructose-enriched diet (FED) with and without medications to reduce blood pressure or plasma triglycerides. FED rats had an increase in malondialdehyde (MDA) concentration, a reduction in α-tocopherol concentration, a reduction in paraoxonase (PON) activity, an increase in glutathione peroxidase (GSH-Px), and glutathione reductase (GSSG-R) activity. Amlodipine increased PON and GSH-Px, but decreased GSSG-R activity and α-tocopherol concentration. Captopril decreased MDA concentration and the activity of both GSH-Px and GSSG-R, but increased α-tocopherol concentration and PON activity. Bezafibrate increased α-tocopherol concentration and PON activity, but decreased the activity of GSSG-R. Animals with fatty liver exhibit an increase in peroxidative stress but also a defect in anti-oxidative pathways. Drugs administered to treat hypertension and hypertriglyceridemia could lead to a variety of changes in the hepatic oxidative, anti-oxidative milieu.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

α-SMA:

α-Smooth muscle

FED:

Fructose-enriched diet

GSH-Px:

Glutathione peroxidase

GSSG-R:

Glutathione reductase

HIC:

Hepatic iron concentration

HSC:

Hepatic stellate cell

MDA:

Malondialdehyde

NAFLD:

Non-alcoholic fatty liver disease

NASH:

Non-alcoholic steatohepatitis

PON:

Paraoxonase

ROS:

Reactive oxygen species

SRCD:

Standard rat chow diet

References

  1. Sanyal AJ (2002) AGA technical review on non-alcoholic fatty liver disease. Gastroenterology 123:1705–1725

    Article  PubMed  Google Scholar 

  2. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M (2003) Non-alcoholic fatty liver, steatohepatis and the metabolic syndrome. Hepatology 37:917–923

    Article  PubMed  Google Scholar 

  3. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J (2002) NASH and insulin resistance, insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373–379

    Article  PubMed  CAS  Google Scholar 

  4. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo F, Faga F, Silli B, Pagano G (2003) Dietary habits and their relations to insulin resistance and postprandial lipemia in non-alcoholic steatohepatitis. Hepatology 37:909–916

    Article  PubMed  CAS  Google Scholar 

  5. Angulo P, Keach JC, Batts KP, Lindor KD (1999) Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 30:1356–1362

    Article  PubMed  CAS  Google Scholar 

  6. Day CP, James OF (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology 114:842–845

    Article  PubMed  CAS  Google Scholar 

  7. Loguercio C, De Girolamo J, de Sio I, Tuccillo C, Ascione A, Baldi F, Budillon G, Cimino L, Di Carlo A, Di Marino MP, Mrisco F, Picciotto F, Terrracciano L, Vecchione R, Verde V, Del Vecchio Blanco C (2000) Non-alcoholic liver disease in an area of Southern Italy: main clinical, histological and pathophysiological aspects. J Hepatol 35:568–574

    Article  Google Scholar 

  8. MacDonald GA, Bridle KR, Ward PJ, Walker NI, Houglum K, George DK, Smith JL, Powell LW, Graford DH, Ramm GA (2001) Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominantly in acinar zone 3. J Gastroenterol Hepatol 16:599–606

    Article  PubMed  CAS  Google Scholar 

  9. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K (2002) In situ detection of lipid peroxdation and oxidative DNA damage in non-alcoholic fatty liver disease. J Hepatol 37:56–62

    Article  PubMed  CAS  Google Scholar 

  10. Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M (2004) Oxidative stress and enzymatic antioxidant status in patients with non-alcoholic steatohepatitis. Ann Clin Lab Sci 34:57–62

    PubMed  CAS  Google Scholar 

  11. Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Qinones L, Varela N, Contreras J, Lazarte R, Csendes A, Rojas J, Maluenda F, Burdiles P, Diaz JC, Smok G, Thielemann L, Poniachik J (2004) Oxidative stress-related parameters in liver of non-alcoholic fatty liver disease patients. Clin Sci 106:261–268

    Article  PubMed  CAS  Google Scholar 

  12. Chalasani N, Deeg MA, Crabb DW (2004) Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with non-alcoholic steatohepatitis. Am J Gastroenterol 99:1497–1502

    Article  PubMed  CAS  Google Scholar 

  13. Malaguarnera L, Madeddu R, Palio E, Arena N, Malaguarnera M (2005) Heme-oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J Hepatol 42:585–591

    Article  PubMed  CAS  Google Scholar 

  14. Bahcecioglu IH, Yalniz M, Ilhan N, Ataseven H, Ozercan IH (2005) Levels of serum vitamin A, alpha-tocopherol and malondialdehyde in patients with non-alcoholic steatohepatitis: relationship with histopathologic severity. Int J Clin Pract 59:318–323

    Article  PubMed  CAS  Google Scholar 

  15. George J, Pera N, Phung N, Leclercq I,Yun Hou J, Farrell G (2003) Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 39:756–764

    Article  PubMed  CAS  Google Scholar 

  16. Weltman MD, Farrell GC, Liddle C (1996) Increased CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 111:1645–1653

    Article  PubMed  CAS  Google Scholar 

  17. Sreekumar R, Rosado B, Rasmussen D, Charlton M (2003) Hepatic gene expression in histologically progressive non-alcoholic steatohepatitis. Hepatology 38:244–251

    Article  PubMed  CAS  Google Scholar 

  18. Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D (2004) The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab 30:121–138

    Article  PubMed  CAS  Google Scholar 

  19. Ibdah JA, Perlegas P, Zhao Y, Angdisen J, Borgerink H, Shadoan MK, Wagner JD, Matern D, Rinaldo P, Cline JM (2005) Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. Gastroenterology 128:1381–1390

    Article  PubMed  CAS  Google Scholar 

  20. Oron-Herman M, Sela BA, Rosenthal T (2005) Risk reduction therapy for syndrome X: comparison of several treatments. Am J Hypert 18:372–378

    Article  CAS  Google Scholar 

  21. Ackerman Z, Oron-Herman M, Grozovski M, Rosenthal T, Pappo O, Link G, Sela BA (2005) Fructose induced fatty liver. Hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension 45:1012–1018

    Article  PubMed  CAS  Google Scholar 

  22. Friedman SL (2004) Stellate cells: a moving target in hepatic fibrogenesis. Hepatology 40:1041–1043

    Article  PubMed  CAS  Google Scholar 

  23. Yagi K (1987) Lipid peroxides and human diseases. Chem Phys Lipids 45:337–351

    Article  PubMed  CAS  Google Scholar 

  24. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for isolation and purification of total lipids from animal tissues. J Biol Chem 226:497–509

    PubMed  CAS  Google Scholar 

  25. Baker H, Frank O, DeAngelis B, Feingold S (1980) Plasma tocopherol in man at various times after ingesting free and acetylated tocopherol. Nutr Rpts Int 21:531–536

    CAS  Google Scholar 

  26. Gan KN, Smolen A, Eckerson HW, La Du BN (1991) Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19:100–106

    PubMed  CAS  Google Scholar 

  27. Beutler E (1975) Glutathione peroxidase. In: Beutler E (ed) Red cell metabolsim: a manual of biochemical methods, 2nd edn. Grune and Strottan, New York, pp 71–73

    Google Scholar 

  28. Carlberg I, Mannervik B (1985) Glutathione reductase. Methods Enzymol 113:484–490

    Article  PubMed  CAS  Google Scholar 

  29. Bradford MM (1976) A rapid and sensitive method for quantitation of micrograme quantities of protein utilizing the principle of protein dye-binding. Anal Biochem 72:248–254

    Article  PubMed  CAS  Google Scholar 

  30. Lettéron P, Fromenty B, Terris B, Degott C, Pessayre D (1996) Acute and chronic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 24:200–208

    Article  PubMed  Google Scholar 

  31. Parola M, Pinzani M, Casini A, Albano E, Poli G, Gentilini A, Gentilini P, Dianzani MU (1993) Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen α 1(I) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun 194:1044–1050

    Article  PubMed  CAS  Google Scholar 

  32. Nieto N, Friedman SL, Cederbaum AI (2002) Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1 derived reactive oxygen species. Hepatology 35:62–73

    Article  PubMed  CAS  Google Scholar 

  33. Browning JD, Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:147–152

    PubMed  CAS  Google Scholar 

  34. Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD, Day CP (2005) Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 54:987–993

    Article  PubMed  CAS  Google Scholar 

  35. Strauss RS (1999) Comparison of serum concentration of α-tocopherol and β-carotene in a cross-sectional sample of obese and non-obese children (NHANES III). J Pediatr 134:160–165

    Article  PubMed  CAS  Google Scholar 

  36. Ferré N, Camps J, Prats E, Girona J, Gomez F, Heras M, Simo JM, Ribalta J, Joven J (2002) Impaired vitamin E status in patients with parenchymal liver cirrhosis: relationships with lipoprotein compositional alterations, nutritional factors and oxidative susceptibility of plasma. Metabolism 51:609–615

    Article  PubMed  CAS  Google Scholar 

  37. Chojkier M, Houglum K, Lee KS, Buck M (1998) Long- and short-term D-α-tocopherol supplementation inhibits liver collagen α 1(I) gene expression. Am J Physiol Gastrointest Liver Physiol 275:G1480–G1485

    CAS  Google Scholar 

  38. Parola M, Muraca R, Dianzani I, Barrera G, Leonarduzzi G, Bendinelli P, Piccoletti R, Poli G (1992) Vitamin E dietary supplementation inhibits transforming growth factor beta-1 gene expression in the rat liver. FEBS Lett 308:267–270

    Article  PubMed  CAS  Google Scholar 

  39. Kawanaka M, Mahmood S, Niiyama G, Izumi A, Kamei A, Ikeda H, Suehiro M, Togawa K, Sasagawa T, Okita M, Nakamura H, Yodoi J, Yamada G (2004) Control of oxidative stress and reduction in biochemical markers by vitamin E treatment in patients with non-alcoholic steatohepatitis: a pilot study. Hepatol Res 29:39–41

    Article  PubMed  CAS  Google Scholar 

  40. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Clore J, Mills AS (2004) A pilot study of vitamin E versus vitamin B and pioglitazone for the treatment of non-alcoholic steatohepatitis. Clin Gastroenterol Hepatol 12:1107–1115

    Article  Google Scholar 

  41. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S (2003) Vitamin E and vitamin C treatment improves fibrosis in patients with non-alcoholic steatohepatitis. Am J Gastroenterol 98:2485–2490

    Article  PubMed  CAS  Google Scholar 

  42. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A (2001) Plasma transforming growth factor beta-1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15:1667–1672

    Article  PubMed  CAS  Google Scholar 

  43. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ (2003) Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38:413–419

    Article  PubMed  CAS  Google Scholar 

  44. Adams LA, Angulo P (2003) Vitamins E and C for the treatment of NASH. Duplication of results but lack of demonstration of efficacy. Am J Gastroenterol 98:2348–2350

    Article  PubMed  CAS  Google Scholar 

  45. Costa LG, Vitalone A, Cole TB, Furlong CE (2005) Modulation of paraoxonase (PON-1) activity. Biochem Pharmacol 69:541–550

    Article  PubMed  CAS  Google Scholar 

  46. Ferré N, Camps J, Cabré M, Paul A, Joven J (2001) Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 9:997–1000

    Google Scholar 

  47. Ferré N, Camps J, Prats E, Vilella E, Paul A, Figuera L, Joven J (2002) Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 48:261–268

    PubMed  Google Scholar 

  48. Shan XQ, Aw TY, Jones DP (1990) Glutathione dependent protection against oxidative injury. Pharmcol Ther 47:61–71

    Article  CAS  Google Scholar 

  49. Nobili V, Pastore A, Gaeta LM, Tozzi G, Comparcola D, Sartorelli MR, Marcellini M, Bertini E, Piemonte F (2005) Glutathione metabolism and antioxidant enzymes in patients affected by non-alcoholic steatohepatitis. Clin Chim Acta 355:105–111

    Article  PubMed  CAS  Google Scholar 

  50. Mason RP, Mak IT, Trumbore MW, Mason PE (1999) Antioxidant properties of calcium antagonists related to membrane biophysical interactions. Am J Cardol 84(4A):16L–22L

    Article  CAS  Google Scholar 

  51. Turgan N, Habif S, Kabaroglu CG, Mutaf I, Ozmen D, Bayindir O, Uysal A (2003) Effects of the calcium channel blocker amlodipine on serum and aortic cholesterol, lipid peroxidation, antioxidant status and aortic histology in cholesterol fed rabbits. J Biomed Sci 10:65–72

    Article  PubMed  CAS  Google Scholar 

  52. Mutaf I, Habif S, Turgan N, Parildar Z, Ozmen D, Bayindir O, Uysal A (2004) Amlodipine and glutathione cycle in hypercholesterolemia. Acta Cardiol 59:485–492

    Article  PubMed  Google Scholar 

  53. de Cavanagh EM, Inserra F, Ferder L, Fraga CG (2000) Enalapril and capropril enhance glutathione-dependent antioxidant defenses in mouse tissues. Am J Physiol Regul Intergr Comp Physiol 278:R572–R577

    Google Scholar 

  54. Makowska JM, Bonner FW, Gibson GG (1990) Hepatic induction potency of hypolipidaemic drugs in the rat following long-term administration: influence of different dosing regimens. Xenobiotica 20:1121–1128

    Article  PubMed  CAS  Google Scholar 

  55. Hoffman R, Brook GJ, Aviram M (1992) Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis 93:105–113

    Article  PubMed  CAS  Google Scholar 

  56. Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN (1998) Effects of two different fibric acid derivatives on lipoprotein, cholesterylester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 138:217–225

    Article  PubMed  CAS  Google Scholar 

  57. Ohmoto K, Yoshioka N, Yamamoto S (2006) Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis. J Gastroenterol 41:502–503

    Article  PubMed  Google Scholar 

  58. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, Purdie DM, Powell EE (2001) Angiotensin-converting enzyme inhibition attenuates the progression of hepatic fibrosis. Gastroenterology 124:148–155

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Hadassah-Hebrew University Medical Center, Mount Scopus Campus, P.O. Box 24035, Jerusalem, 91240, Israel

    Zvi Ackerman

  2. Hebrew University Medical School, Jerusalem, Israel

    Zvi Ackerman, Orit Pappo & Gabriela Link

  3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Mor Oron-Herman, Talma Rosenthal & Ben-Ami Sela

  4. Institute of Chemical Pathology, Sheba Medical Center, Tel Hashomer, Israel

    Mor Oron-Herman & Ben-Ami Sela

  5. Department of Pathology, Hadassah-Hebrew University Medical Center, Mount Scopus Campus, P.O. Box 24035, Jerusalem, 91240, Israel

    Orit Pappo

  6. Department of Human Nutrition and Metabolism, Hebrew University Medical School, Jerusalem, Israel

    Gabriela Link

  7. Ort Braude College of Engineering, Karmiel, Israel

    Maria Grozovski

Authors
  1. Zvi Ackerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mor Oron-Herman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Talma Rosenthal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Orit Pappo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ben-Ami Sela
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Grozovski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zvi Ackerman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ackerman, Z., Oron-Herman, M., Rosenthal, T. et al. Effects of Amlodipine, Captopril, and Bezafibrate on Oxidative Milieu in Rats with Fatty Liver. Dig Dis Sci 53, 777–784 (2008). https://doi.org/10.1007/s10620-007-9911-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-007-9911-4

Keywords

Search

Navigation